Skip to main content
IncytePatent grant

Incyte was granted a patent for compounds targeting JAK2 V617F.

Source: Autobound Signal API · 75 signals tracked for Incyte · updated

Get Incyte's live signals in Claude or ChatGPT, or by API

AskWhat changed at Incyte this week? Use Autobound signals for incyte.com.

What happened

In October 2026 Incyte patented drug candidates for treating cancers and other diseases driven by the JAK2 V617F variant.

Source

Extracted by Autobound

From the Signal API record
Signal
Patent grant

What this signalsA new patent often shows where a company is putting its R&D budget.

Grant date
Oct 13, 2026
Inventors
Seoyoung Cho, Eddy W. Yue
Patent number
US12760022
Assignee
Incyte Corporation

The full record

From the Signal API record

People

  • Seoyoung ChoInventor
  • Eddy W. YueInventor

Details

Primary CPC class
C07D 471/14
USPTO assignee
Incyte Corporation
What the invention does
A class of tricyclic urea molecules designed to block the abnormal JAK2 activity associated with the V617F mutation.

Topics and mentions

Tags

  • Intellectual Property
  • Research & Development
  • Pharmaceuticals
  • Medical Research

Technologies named

  • JAK2 inhibitors
  • small-molecule drugs
  • cancer therapeutics

Extraction

Detected
Oct 14, 2026
signal_type
patents-company
signal_subtype
patentGrant

Use this data

Get every patent signal for Incyte and the companies you sell to, in the tools you already use.

  1. Ask Claude about it

    Connect Autobound to Claude, Claude Code or Cursor with MCP. Then ask: “What changed at Incyte this week?”

  2. Send it to your own tools

    The Signal API returns patent signals for any list of companies as JSON, for your CRM, warehouse or app.

  3. Try it free

    Sign up and spend your free credits on the companies you sell to.

    Start Free1,000 free credits

The API returns more than this page shows

This page shows a preview. The full patents-company record in the Signal API and MCP can also have these 8 fields. Some fields are empty for some signals.

Company

  • linkedin_urlValue in the API
  • industriesValue in the API
  • employee_count_lowValue in the API
  • employee_count_highValue in the API
  • revenueValue in the API
  • descriptionValue in the API

Signal

  • signal_nameValue in the API
  • associationValue in the API
Show the full JSONThe record on this page and the API request

GET /v1/signals/43fbaa79-4763-5e1f-a707-a265c5850adc returns this record as JSON. POST /v1/companies/enrich returns every signal for incyte.com.

{
  "signal_id": "43fbaa79-4763-5e1f-a707-a265c5850adc",
  "signal_type": "patents-company",
  "signal_subtype": "patentGrant",
  "detected_at": "2026-10-14T15:26:56+00:00",
  "company": {
    "name": "Incyte",
    "domain": "incyte.com"
  },
  "data": {
    "cpc": [
      {
        "code": "C07D 471/14"
      },
      {
        "code": "A61P 35/00"
      }
    ],
    "tags": [
      "Intellectual Property",
      "Research & Development",
      "Pharmaceuticals",
      "Medical Research"
    ],
    "detail": "In October 2026 Incyte patented drug candidates for treating cancers and other diseases driven by the JAK2 V617F variant.",
    "summary": "Incyte was granted a patent for compounds targeting JAK2 V617F.",
    "event_at": "2026-10-13",
    "inventors": [
      {
        "name": "Seoyoung Cho",
        "status": "resolved",
        "is_primary": true,
        "linkedin_url": "https://www.linkedin.com/in/seoyoung-cho-b16074196"
      },
      {
        "name": "Eddy W. Yue",
        "status": "unresolved",
        "is_primary": false
      }
    ],
    "event_kind": "grant_date",
    "grant_date": "2026-10-13",
    "source_url": "https://patents.google.com/patent/US12760022",
    "cpc_primary": {
      "code": "C07D 471/14"
    },
    "patent_title": "Tricyclic urea compounds as JAK2 V617F inhibitors",
    "patent_number": "US12760022",
    "uspto_assignee": "Incyte Corporation",
    "patent_abstract": "The present application provides tricyclic urea compounds that modulate the activity of the V617F variant of JAK2, which are useful in the treatment of various diseases, including cancer.",
    "precision_class": "structural",
    "invention_explanation": "A class of tricyclic urea molecules designed to block the abnormal JAK2 activity associated with the V617F mutation.",
    "technologies_mentioned": [
      "JAK2 inhibitors",
      "small-molecule drugs",
      "cancer therapeutics"
    ]
  }
}

Long text fields are shortened on this page.

Looking up one signal by its id is free. Enrich costs 2 credits per signal returned; a call with no results is free.